<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00875901</url>
  </required_header>
  <id_info>
    <org_study_id>UFPTI 0901 - LU03</org_study_id>
    <nct_id>NCT00875901</nct_id>
  </id_info>
  <brief_title>Proton Therapy for Stage I Non-Small Cell Lung Cancer (LU03)</brief_title>
  <acronym>LU03</acronym>
  <official_title>Hypofractionated, Image-Guided Radiation Therapy With Proton Therapy for Stage I Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a research study to determine if hypofractionated image guided radiation therapy
      (hypoIGRT) with proton therapy is a good way to treat early stage lung tumors for patients
      who will not have surgery. HypoIGRT delivers higher daily doses of radiation over a shorter
      period of time compared with conventional radiation. This is thought to deliver a more lethal
      dose of radiation to the tumor and is more convenient with treatment being completed within
      2-3 weeks compared to the typical 7-8 week course of conventional radiotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Anticipated">April 2032</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirm Grade 3 or higher toxicity rate of hypoIGRT proton therapy in patients with stage I non-small cell lung cancer.</measure>
    <time_frame>1 year after the end of radiation therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Collect and analyze outcome data on tumor control and survival</measure>
    <time_frame>When each patient has been followed for a minimum of 12 months to a maximum of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess differences in dosimetric values compared with photons for lung, heart, esophagus, spinal cord, skin and brachial plexus</measure>
    <time_frame>When each patient has been followed for a minimum of 12 months to a maximum of 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess changes in quality of life before and after treatment</measure>
    <time_frame>Before treatment and then when each patient has been followed for a minimum of 12 months to a maxiumum of 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">23</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Peripherally located lung tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12 cobalt gray equivalent per fraction to a total of 48 cobalt gray equivalent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Centrally located lung tumor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Peripherally located lung tumor</intervention_name>
    <description>12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)</description>
    <arm_group_label>Peripherally located lung tumor</arm_group_label>
    <other_name>Proton Radiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Centrally located lung tumor</intervention_name>
    <description>6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)</description>
    <arm_group_label>Centrally located lung tumor</arm_group_label>
    <other_name>Proton Radiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed, by biopsy or cytology, non-small cell lung carcinoma
             diagnosed within 3 months prior to study enrollment.

          -  T1, N0, M0 or T2, N0, M0. (AJCC Lung 7th Edition)

          -  At least 18 years old at the time of consent.

          -  Adequate bone marrow function.

          -  Medically inoperable. Medically operable candidates are allowed if they refuse
             surgical resection.

          -  If the patient has a large pleural effusion, it must be biopsy negative.

        Exclusion Criteria:

          -  Evidence of distant metastasis (M1) and/or nodal involvement (N1, N2, N3).

          -  Synchronous primary.

          -  T2 tumors &gt; 5 cm; T3, T4 primary tumor.

          -  Previous radiotherapy for lung cancer.

          -  Concomitant local, regional, and/or systemic therapy during radiotherapy.

          -  Active systemic, pulmonary, and/or pericardial infection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bradford S Hoppe, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida Proton Therapy Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Intake Coordinator</last_name>
    <phone>877-686-6009</phone>
  </overall_contact>
  <location>
    <facility>
      <name>University of Florida Proton Therapy Institute</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intake Coordinator</last_name>
      <phone>877-686-6009</phone>
    </contact>
    <investigator>
      <last_name>Bradford S Hoppe, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.floridaproton.org/contact/contact.html</url>
    <description>Contact the University of Florida Proton Therapy Institute</description>
  </link>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ. Cancer statistics, 2008. CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96. doi: 10.3322/CA.2007.0010. Epub 2008 Feb 20.</citation>
    <PMID>18287387</PMID>
  </reference>
  <reference>
    <citation>al-Kattan K, Sepsas E, Fountain SW, Townsend ER. Disease recurrence after resection for stage I lung cancer. Eur J Cardiothorac Surg. 1997 Sep;12(3):380-4.</citation>
    <PMID>9332915</PMID>
  </reference>
  <reference>
    <citation>Suzuki K, Nagai K, Yoshida J, Moriyama E, Nishimura M, Takahashi K, Nishiwaki Y. Prognostic factors in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 1999 Apr;67(4):927-32.</citation>
    <PMID>10320230</PMID>
  </reference>
  <reference>
    <citation>van Rens MT, de la Rivi√®re AB, Elbers HR, van Den Bosch JM. Prognostic assessment of 2,361 patients who underwent pulmonary resection for non-small cell lung cancer, stage I, II, and IIIA. Chest. 2000 Feb;117(2):374-9.</citation>
    <PMID>10669677</PMID>
  </reference>
  <reference>
    <citation>Dosoretz DE, Galmarini D, Rubenstein JH, Katin MJ, Blitzer PH, Salenius SA, Dosani RA, Rashid M, Mestas G, Hannan SE, et al. Local control in medically inoperable lung cancer: an analysis of its importance in outcome and factors determining the probability of tumor eradication. Int J Radiat Oncol Biol Phys. 1993 Oct 20;27(3):507-16.</citation>
    <PMID>8226142</PMID>
  </reference>
  <reference>
    <citation>Dosoretz DE, Katin MJ, Blitzer PH, Rubenstein JH, Salenius S, Rashid M, Dosani RA, Mestas G, Siegel AD, Chadha TT, et al. Radiation therapy in the management of medically inoperable carcinoma of the lung: results and implications for future treatment strategies. Int J Radiat Oncol Biol Phys. 1992;24(1):3-9.</citation>
    <PMID>1324899</PMID>
  </reference>
  <reference>
    <citation>Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest. 1995 Nov;108(5):1278-82.</citation>
    <PMID>7587429</PMID>
  </reference>
  <reference>
    <citation>Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn Ericsson S, Johansson KA, Ekberg L, Morhed E, Paludan M, Wittgren L, Blomgren H, Lewensohn R. Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol. 2006;45(7):787-95.</citation>
    <PMID>16982541</PMID>
  </reference>
  <reference>
    <citation>Fritz P, Kraus HJ, Blaschke T, M√ºhlnickel W, Strauch K, Engel-Riedel W, Chemaissani A, Stoelben E. Stereotactic, high single-dose irradiation of stage I non-small cell lung cancer (NSCLC) using four-dimensional CT scans for treatment planning. Lung Cancer. 2008 May;60(2):193-9. Epub 2007 Nov 28.</citation>
    <PMID>18045732</PMID>
  </reference>
  <reference>
    <citation>Lagerwaard FJ, Haasbeek CJ, Smit EF, Slotman BJ, Senan S. Outcomes of risk-adapted fractionated stereotactic radiotherapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2008 Mar 1;70(3):685-92. doi: 10.1016/j.ijrobp.2007.10.053. Epub 2007 Dec 31.</citation>
    <PMID>18164849</PMID>
  </reference>
  <reference>
    <citation>Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, Kimura T, Takeda A, Ouchi A, Hareyama M, Kokubo M, Hara R, Itami J, Yamada K, Araki T. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007 Jul;2(7 Suppl 3):S94-100.</citation>
    <PMID>17603311</PMID>
  </reference>
  <reference>
    <citation>Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, Ewing M, Abdulrahman R, DesRosiers C, Williams M, Fletcher J. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006 Oct 20;24(30):4833-9.</citation>
    <PMID>17050868</PMID>
  </reference>
  <reference>
    <citation>Xia T, Li H, Sun Q, Wang Y, Fan N, Yu Y, Li P, Chang JY. Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2006 Sep 1;66(1):117-25. Epub 2006 Jun 9.</citation>
    <PMID>16765528</PMID>
  </reference>
  <reference>
    <citation>Hof H, Muenter M, Oetzel D, Hoess A, Debus J, Herfarth K. Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC). Cancer. 2007 Jul 1;110(1):148-55.</citation>
    <PMID>17516437</PMID>
  </reference>
  <reference>
    <citation>Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, Molls M. Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol. 2006;45(7):796-801.</citation>
    <PMID>16982542</PMID>
  </reference>
  <reference>
    <citation>Yamashita H, Nakagawa K, Nakamura N, Koyanagi H, Tago M, Igaki H, Shiraishi K, Sasano N, Ohtomo K. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol. 2007 Jun 7;2:21.</citation>
    <PMID>17553175</PMID>
  </reference>
  <reference>
    <citation>Onimaru R, Shirato H, Shimizu S, Kitamura K, Xu B, Fukumoto S, Chang TC, Fujita K, Oita M, Miyasaka K, Nishimura M, Dosaka-Akita H. Tolerance of organs at risk in small-volume, hypofractionated, image-guided radiotherapy for primary and metastatic lung cancers. Int J Radiat Oncol Biol Phys. 2003 May 1;56(1):126-35.</citation>
    <PMID>12694831</PMID>
  </reference>
  <reference>
    <citation>Georg D, Hillbrand M, Stock M, Dieckmann K, P√∂tter R. Can protons improve SBRT for lung lesions? Dosimetric considerations. Radiother Oncol. 2008 Sep;88(3):368-75. doi: 10.1016/j.radonc.2008.03.007. Epub 2008 Apr 9.</citation>
    <PMID>18405986</PMID>
  </reference>
  <reference>
    <citation>Bush DA, Slater JD, Shin BB, Cheek G, Miller DW, Slater JM. Hypofractionated proton beam radiotherapy for stage I lung cancer. Chest. 2004 Oct;126(4):1198-203.</citation>
    <PMID>15486383</PMID>
  </reference>
  <reference>
    <citation>Miyamoto T, Baba M, Sugane T, Nakajima M, Yashiro T, Kagei K, Hirasawa N, Sugawara T, Yamamoto N, Koto M, Ezawa H, Kadono K, Tsujii H, Mizoe JE, Yoshikawa K, Kandatsu S, Fujisawa T; Working Group for Lung Cancer. Carbon ion radiotherapy for stage I non-small cell lung cancer using a regimen of four fractions during 1 week. J Thorac Oncol. 2007 Oct;2(10):916-26.</citation>
    <PMID>17909354</PMID>
  </reference>
  <reference>
    <citation>Lagerwaard FJ et al Quality of life after stereotactic radiotherapy for medically inoperable stage I lung cancer. International Journal of Radiation Oncology, Biology, Physics IJROBP 2006 Nov1;66(3): S133-S134</citation>
  </reference>
  <reference>
    <citation>Brown J, Thorpe H, Napp V, Fairlamb DJ, Gower NH, Milroy R, Parmar MK, Rudd RM, Spiro SG, Stephens RJ, Waller D, West P, Peake MD. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer. J Clin Oncol. 2005 Oct 20;23(30):7417-27. Epub 2005 Sep 12.</citation>
    <PMID>16157935</PMID>
  </reference>
  <reference>
    <citation>Li WW, Lee TW, Lam SS, Ng CS, Sihoe AD, Wan IY, Yim AP. Quality of life following lung cancer resection: video-assisted thoracic surgery vs thoracotomy. Chest. 2002 Aug;122(2):584-9.</citation>
    <PMID>12171836</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2009</study_first_submitted>
  <study_first_submitted_qc>April 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2009</study_first_posted>
  <last_update_submitted>May 22, 2018</last_update_submitted>
  <last_update_submitted_qc>May 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lung Cancer</keyword>
  <keyword>Stage I Non-Small Cell Lung Cancer</keyword>
  <keyword>Proton Radiation</keyword>
  <keyword>HypoIGRT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cobalt</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

